Cargando…

Relation of Statin Use with Esophageal Cancer

The present study evaluated the association of long-term statin use with the diagnosis and mortality of esophageal cancer in a Korean population. The Korean National Health Insurance Service-Health Screening Cohort from 2002 to 2019 was enrolled. Esophageal cancer patients were matched with control...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Sarang, Choi, Hyo Geun, Kwon, Mi Jung, Kim, Ji Hee, Kim, Joo-Hee, Kim, So Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305244/
https://www.ncbi.nlm.nih.gov/pubmed/37375847
http://dx.doi.org/10.3390/ph16060900
_version_ 1785065687744512000
author Jang, Sarang
Choi, Hyo Geun
Kwon, Mi Jung
Kim, Ji Hee
Kim, Joo-Hee
Kim, So Young
author_facet Jang, Sarang
Choi, Hyo Geun
Kwon, Mi Jung
Kim, Ji Hee
Kim, Joo-Hee
Kim, So Young
author_sort Jang, Sarang
collection PubMed
description The present study evaluated the association of long-term statin use with the diagnosis and mortality of esophageal cancer in a Korean population. The Korean National Health Insurance Service-Health Screening Cohort from 2002 to 2019 was enrolled. Esophageal cancer patients were matched with control participants for demographic variables. The statin prescription histories were collected and grouped into <180 days, 180 to 545 days, and >545 days of duration. Propensity score overlap weighting was applied to minimize the bias between the esophageal cancer and control groups. The odds ratios (ORs) of the duration of statin use for esophageal cancer were analyzed using propensity score overlap weighted multivariable logistic regression analysis. The esophageal cancer group was classified as dead and surviving patients, and the ORs of the duration of statin use for the mortality of esophageal cancer were analyzed in an identical manner. Secondary analyses were conducted according to comorbid factors. Patients with esophageal cancer did not show lower odds for the duration of statin prescription in the overall study population (OR = 1.30, 95% CI = 1.03–1.65, p = 0.027 for 180 to 545 days and OR = 1.29, 95% CI = 1.08–1.55, p = 0.006 for >545 days). Subgroups of nonsmokers, past and current smokers, alcohol consumption ≥ 1 time a week, SBP < 140 mmHg and DBP < 90 mmHg, fasting blood glucose ≥ 100 mg/dL, total cholesterol ≥ 200 mg/dL, CCI score = 0, and nondyslipidemia history demonstrated low odds for the duration of statin prescription. Both types of statins, hydrophilic and lipophilic statins, were not related to a lower rate of esophageal cancer. The mortality of esophageal cancer was not associated with the duration of statin prescription. A subgroup with total cholesterol ≥ 200 mg/dL showed lower odds of statin prescription for mortality of esophageal cancer. The duration of statin prescription was not related to a lower rate or mortality of esophageal cancer in the adult Korean population.
format Online
Article
Text
id pubmed-10305244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103052442023-06-29 Relation of Statin Use with Esophageal Cancer Jang, Sarang Choi, Hyo Geun Kwon, Mi Jung Kim, Ji Hee Kim, Joo-Hee Kim, So Young Pharmaceuticals (Basel) Article The present study evaluated the association of long-term statin use with the diagnosis and mortality of esophageal cancer in a Korean population. The Korean National Health Insurance Service-Health Screening Cohort from 2002 to 2019 was enrolled. Esophageal cancer patients were matched with control participants for demographic variables. The statin prescription histories were collected and grouped into <180 days, 180 to 545 days, and >545 days of duration. Propensity score overlap weighting was applied to minimize the bias between the esophageal cancer and control groups. The odds ratios (ORs) of the duration of statin use for esophageal cancer were analyzed using propensity score overlap weighted multivariable logistic regression analysis. The esophageal cancer group was classified as dead and surviving patients, and the ORs of the duration of statin use for the mortality of esophageal cancer were analyzed in an identical manner. Secondary analyses were conducted according to comorbid factors. Patients with esophageal cancer did not show lower odds for the duration of statin prescription in the overall study population (OR = 1.30, 95% CI = 1.03–1.65, p = 0.027 for 180 to 545 days and OR = 1.29, 95% CI = 1.08–1.55, p = 0.006 for >545 days). Subgroups of nonsmokers, past and current smokers, alcohol consumption ≥ 1 time a week, SBP < 140 mmHg and DBP < 90 mmHg, fasting blood glucose ≥ 100 mg/dL, total cholesterol ≥ 200 mg/dL, CCI score = 0, and nondyslipidemia history demonstrated low odds for the duration of statin prescription. Both types of statins, hydrophilic and lipophilic statins, were not related to a lower rate of esophageal cancer. The mortality of esophageal cancer was not associated with the duration of statin prescription. A subgroup with total cholesterol ≥ 200 mg/dL showed lower odds of statin prescription for mortality of esophageal cancer. The duration of statin prescription was not related to a lower rate or mortality of esophageal cancer in the adult Korean population. MDPI 2023-06-19 /pmc/articles/PMC10305244/ /pubmed/37375847 http://dx.doi.org/10.3390/ph16060900 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jang, Sarang
Choi, Hyo Geun
Kwon, Mi Jung
Kim, Ji Hee
Kim, Joo-Hee
Kim, So Young
Relation of Statin Use with Esophageal Cancer
title Relation of Statin Use with Esophageal Cancer
title_full Relation of Statin Use with Esophageal Cancer
title_fullStr Relation of Statin Use with Esophageal Cancer
title_full_unstemmed Relation of Statin Use with Esophageal Cancer
title_short Relation of Statin Use with Esophageal Cancer
title_sort relation of statin use with esophageal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305244/
https://www.ncbi.nlm.nih.gov/pubmed/37375847
http://dx.doi.org/10.3390/ph16060900
work_keys_str_mv AT jangsarang relationofstatinusewithesophagealcancer
AT choihyogeun relationofstatinusewithesophagealcancer
AT kwonmijung relationofstatinusewithesophagealcancer
AT kimjihee relationofstatinusewithesophagealcancer
AT kimjoohee relationofstatinusewithesophagealcancer
AT kimsoyoung relationofstatinusewithesophagealcancer